- Cierre anterior
3,5600 - Abrir
3,5700 - Oferta 3,6700 x --
- Precio de compra 3,6800 x --
- Rango diario
3,5700 - 3,6850 - Intervalo de 52 semanas
2,2600 - 3,9800 - Volumen
157.347 - Prom. volumen
43.967 - Capitalización de mercado (intradía)
336,485M - Beta (5 años al mes) 0,75
- Ratio precio/beneficio (TMTM)
26,29 - BPA (TTM):
0,1400 - Fecha de beneficios 15 nov 2024
- Previsión de rentabilidad y dividendo 0,10 (2,70%)
- Fecha de exdividendo 8 jul 2024
- Objetivo est 1a
--
Ercros, S.A. manufactures and sells basic chemicals, intermediate chemicals, and pharmaceuticals in Spain. It operates through three segments: Chlorine Derivatives, Intermediate Chemicals, and Pharmacy. The Chlorine Derivatives segment produces ammonia, bioplastics, caustic potash and soda, chlorine, chloroisocyanurates, dicalcium phosphate, dichloroethane, hydrochloric acid, hydrogen peroxide, potassium carbonate, PVC compounds, sodium chlorate and chlorite, sodium hypochlorite, and vinyl chloride monomers and polychloride. This segment's products are used as intermediates in other industrial processes to purify and treat drinking and waste water; treat and maintain swimming pool water; bleach fabrics and paper; produce solvents, detergents, and strippers; manufacture printing inks and coloring; to produce compound feed and in cooling equipment. The Intermediate Chemicals segment provides formaldehyde, glues and resins, molding compunds, paraformaldehyde, pentaerythritol and dipentaerythritol, and sodium formate for manufacturing of particle, and decorative laminates and plywoods, as well as resins, paints, and varnishes in the furniture and decoration industry; sockets and switches in the electrical components sector; and tableware, and health and packaging items in the textile tanning industry. The Pharmacy division engages in the production of raw materials and pharmaceutical intermediate products from antibiotic, cholesterol-lowering, anti-ulcer, and anti-fungal agents. This segment's products include amlodipine besylate, azithromycin, clarithromycin, erythromycins, famotidine, fosfomycin calcium and sodium, fosfomycin trometamol, and fusidic acid. The company is also involved in exporting activities. Ercros, S.A. was founded in 1817 and is headquartered in Barcelona, Spain.
www.ercros.es1359
Empleados a tiempo completo
31 de diciembre
Año fiscal finalizado
Basic Materials
Sector
Chemicals
Sector
Noticias relacionadas
Ver más
Descripción general del rendimiento: ECR.MC
Rentabilidad total acumulada hasta el 10/10/2024, que puede incluir dividendos u otras distribuciones. El valor de referencia es
.Rentabilidad hasta la fecha
Rendimiento en 1 año(s)
Rendimiento en 3 año(s)
Rendimiento en 5 año(s)
Comparar con: ECR.MC
Selecciona hasta 4 acciones para analizar empresas similares utilizando métricas clave de rendimiento.
Estadísticas: ECR.MC
Ver másMedidas de valoración
Capitalización de mercado
325.51M
Valor de empresa
442.14M
P/E últimos 12 meses
25.57
Precio/beneficio anticipado
14.24
Ratio precio-expectativas de beneficio (5 años previstos)
0.32
Precio/ventas (ttm)
0.51
Precio/valor (tmr)
0.92
Valor/Ingresos de la empresa
0.69
Valor/EBITDA de empresa
20.37
Destacados financieros
Rentabilidad y estado de resultados
Margen de beneficios
1,89%
Rentabilidad económica (ttm)
-1,98%
Rentabilidad financiera (ttm)
3,52%
Ingresos (ttm)
657,22M
Ingresos netos disponibles (ttm)
12,44M
BPA diluido (ttm)
0,1400
Hoja de balance y flujo de caja
Efectivo total (tmr)
44,87M
Endeudamiento/Patrimonio total (tmr)
45,05%
Flujo de efectivo apalancado (ttm)
2,9M